Research & Evidence

Trial design, systematic reviews, medical statistics, and guideline updates.

  • 4 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Research & Evidence


clinicaltrialvanguard.com > executiveinterviews > when-the-trial-ends-the-data-work-begins

When the Trial Ends, the Data Work Begins

4+ hour, 2+ min ago   (384+ words) Moe: Why did IAG validate the Ferring proof-of-concept against real-world clinical data rather than expanding the trial dataset? The trial was already finished, the data already collected, so expanding that database was not possible. But it was a great dataset…...


rockdalecitizen.com > features > ask-the-doctors-neuroplasticity-helps-brain-compensate-after-stroke > article_a478fcc8-f7d1-52df-9135-d4c74c22dd62.html

ASK THE DOCTORS: Neuroplasticity helps brain compensate after stroke

6+ hour, 14+ min ago   (261+ words) Rockdale Citizen Dear Doctors: I was diagnosed with cryptogenic ischemic strokes, but I’ve never had a single stroke symptom other than dizziness and balance issues. These had been blamed on an inner-ear infection. How could this happen when Iâ…...


neurosciencenews.com > ai-longevity-vaccine-cellular-aging-31211

AI-Designed???Longevity Vaccines??? Target the Earliest Culprits of Cellular Aging

18+ hour, 12+ min ago   (190+ words) Insilico Medicine has launched a new research initiative called “Longevity Vaccines,” applying generative artificial intelligence and programmable circular RNA (cmRNA) delivered via lipid nanoparticles to instruct a patient’s own immune cells to eliminate senescent, fibrotic, and autoreactive cells. Rather than…...


markets.businessinsider.com > news > stocks > biovie-announces-topline-results-from-phase-2-address-lc-trial-evaluating-bezisterim-for-the-treatment-of-neurological-symptoms-associated-with-long-covid-1036546208

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

1+ day, 2+ hour ago   (199+ words) Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m....


lincolnjournal.com > online_features > press_releases > tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t > article_44f06588-35f3-5396-8bba-eb3117172627.html

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

17+ hour, 39+ min ago   (120+ words) lincolnjournal.com Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Sorry, an error occurred. Account processing issue - the email address may already exist Must be at least 8 characters, not…...


psypost.org > synthetic-cbd-derivative-prevents-seizures-in-mice-without-causing-sedation

Synthetic CBD derivative prevents seizures in mice without causing sedation

17+ hour, 51+ min ago   (564+ words) A new synthetic derivative of cannabidiol, or CBD, reduces seizure severity and promotes healthy brain cell development in mice. The compound, modified to have an elongated chemical tail, protected against chemically induced seizures without causing sedation. The research was published…...